Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...
No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...
Pharmaceutical firm Pfizer is to cut more jobs at its Irish manufacturing facilities, as part of a global cost-cutting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback